Pharma major Wockhardt has received approval form the US FDA for marketing 15 and 30 mg delayed release capsules of Lansoprazole, a medication used in the treatment of peptic ulcer.
This is the generic name for Prevacid brand marketed in the US by Takeda. Wockhardt said it is launching the product immediately.
The company will make the Lansoprazole API at its Ankleshwar facility and the delayed release capsules in Aurangabad. Technology for both has been developed in-house.
According to IMS Health, the total market for this product is $700 million. Wockhardt already markets an OTC version of 15 mg delayed release Lansoprazole capsules in the US.